93 related articles for article (PubMed ID: 8763810)
1. Prospects for immunotherapy in cervical cancer.
Immunol Today; 1996 Jul; 17(7):299. PubMed ID: 8763810
[No Abstract] [Full Text] [Related]
2. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies of human papilloma vaccines in cervical cancer.
Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Evans AS; Mason M
Adv Exp Med Biol; 2001; 495():419-27. PubMed ID: 11774604
[No Abstract] [Full Text] [Related]
4. Towards vaccines against human papillomavirus type-16 genital infections.
Cason J; Khan SA; Best JM
Vaccine; 1993; 11(6):603-11. PubMed ID: 8391738
[TBL] [Abstract][Full Text] [Related]
5. Cancer of the cervix: prospects for immunological control.
Davies DH; McIndoe GA; Chain BM
Int J Exp Pathol; 1991 Apr; 72(2):239-51. PubMed ID: 1849733
[No Abstract] [Full Text] [Related]
6. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
Hara M; Matsueda S; Tamura M; Takedatsu H; Tanaka M; Kawano K; Mochizuki K; Kamura T; Itoh K; Harada M
Int J Oncol; 2005 Nov; 27(5):1371-9. PubMed ID: 16211234
[TBL] [Abstract][Full Text] [Related]
7. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
Gérard CM; Baudson N; Kraemer K; Bruck C; Garçon N; Paterson Y; Pan ZK; Pardoll D
Vaccine; 2001 Mar; 19(17-19):2583-9. PubMed ID: 11257396
[TBL] [Abstract][Full Text] [Related]
9. T-cell therapy for cervical cancer.
Cancer Discov; 2014 Aug; 4(8):862. PubMed ID: 25092728
[No Abstract] [Full Text] [Related]
10. Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer.
Dillner J
Lancet; 1993 Jun; 341(8860):1594. PubMed ID: 8099663
[No Abstract] [Full Text] [Related]
11. Potential immunotherapy targets in recurrent cervical cancer.
Ring KL; Yemelyanova AV; Soliman PT; Frumovitz MM; Jazaeri AA
Gynecol Oncol; 2017 Jun; 145(3):462-468. PubMed ID: 28233576
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
13. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
Schoell WM; Mirhashemi R; Liu B; Janicek MF; Podack ER; Penalver MA; Averette HE
Gynecol Oncol; 1999 Sep; 74(3):448-55. PubMed ID: 10479508
[TBL] [Abstract][Full Text] [Related]
14. Vaccine and antibody-directed T cell tumour immunotherapy.
Dermime S; Gilham DE; Shaw DM; Davidson EJ; Meziane el-K; Armstrong A; Hawkins RE; Stern PL
Biochim Biophys Acta; 2004 Jul; 1704(1):11-35. PubMed ID: 15238242
[TBL] [Abstract][Full Text] [Related]
15. Gearing up T-cell immunotherapy in cervical cancer.
Chauhan SR; Bharadwaj M
Curr Probl Cancer; 2018; 42(2):175-188. PubMed ID: 29776594
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer: prevention, diagnosis, and therapeutics.
Janicek MF; Averette HE
CA Cancer J Clin; 2001; 51(2):92-114; quiz 115-8. PubMed ID: 11577486
[TBL] [Abstract][Full Text] [Related]
17. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer.
van der Sluis TC; van der Burg SH; Arens R; Melief CJ
Curr Opin Immunol; 2015 Aug; 35():9-14. PubMed ID: 26001120
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy.
Santin AD; Bellone S; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Curr Pharm Des; 2005; 11(27):3485-500. PubMed ID: 16248803
[TBL] [Abstract][Full Text] [Related]
20. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer.
Ellis JR; Keating PJ; Baird J; Hounsell EF; Renouf DV; Rowe M; Hopkins D; Duggan-Keen MF; Bartholomew JS; Young LS
Nat Med; 1995 May; 1(5):464-70. PubMed ID: 7585096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
